Background. -The rate of pacemaker implantation is rising. Given that the life expectancy of the population is projected to increase, a large number of elderly patients are likely to be implanted in the future. As pacemaker batteries can last for 8-10 years, an increasing number of pacemaker recipients will require replacement of their devices when they become nonagenarians. Aims. -To analyse the short-and long-term outcomes after device replacement in nonagenarians. Methods. -Patients aged ≥ 90 years referred to a tertiary centre for pacemaker replacement from January 2004 to July 2014 were included retrospectively. Clinical follow-up data were obtained from clinical visits or telephone interviews with patients or their families. The primary clinical endpoint was total mortality. Secondary endpoints included early and delayed procedure-related complications and predictive risk factors for total mortality.
Background
In Europe, 933 pacemakers per million inhabitants are implanted every year [1] . The implantation rate is rising continuously, partly because of the ageing of general population, resulting in an increased risk of developing atrioventricular (AV) block and sinus node dysfunction, but also related to the expansion of indications for cardiac resynchronization therapy (CRT). The average age at device implantation is currently 80 years [2] .
In 2012, life expectancy in Europe was 80.3 years for the general population (83.1 years for women; 77.5 years for men), a 2.6-year increase since 2002 [3] . By 2060, life expectancy is projected to be 89.1 years for women and 84.6 years for men [4] . A 163.4% increase in the number of patients aged ≥ 80 years is expected. To date, only a few studies have specifically reported the long-term outcome of very elderly patients implanted with a cardiac pacemaker. In a recent study, Udo et al. evaluated the outcome of pacemaker recipients aged > 80 years, and reported a cumulative 5-year survival of around 50% after implantation, with a complication rate of 18.1% [5] .
As pacemaker batteries can last for as long as 8-10 years, an increasing number of pacemaker recipients will probably require replacement of their devices when they are nonagenarians. No studies specifically reporting the outcome and survival of nonagenarians referred for pacemaker replacement have been published. Therefore, we aimed to analyse the short-and long-term outcomes after device replacement in these very elderly patients. Procedural characteristics, survival rate and causes of deaths were analysed in the present study.
Methods

Study population
The present study is based on a retrospective analysis of all consecutive patients aged > 90 years referred to our tertiary centre for device replacement from January 2004 to July 2014.
Clinical information was obtained from the patients' medical records, which included patient demographics, medical history, medication use and history of pacing (indication of pacing, age at primary implantation, device type and number of replacements). ''Physiological pacing'' was defined as the implantation of a dual-chamber pacemaker or CRT-pacemaker (CRT-P) in patients in sinus rhythm and a single-chamber pacemaker in patients in atrial fibrillation (AF), while ''non-physiological pacing'' was defined as the implantation of a VVI chamber device in patients in sinus rhythm. The Charlson Co-morbidity Index, a validated score to assess patients' co-morbidities, was evaluated using dedicated scales available online [6, 7] . Various Charlson indexes have been proposed, depending on the number of variables included. We decided, as previously performed by Mandawat et al. in their study of octogenarian and nonagenarian pacemaker recipients, to use the index that does not include age, as all our patients were ≥ 90 years [8] .
The procedural characteristics of the device replacement were recorded, including the type of pacemaker implanted, duration of hospital stay and procedural complications.
Follow-up and outcomes
Clinical follow-up data were obtained from clinical visits or telephone interviews with patients or their families, general practitioners or nurses. The primary clinical endpoint was total mortality over the follow-up period (censor date 1 August 2014).
Causes of death were obtained through hospital discharge notes and inquiries made with the family, the general practitioner or nursing homes, and were classified using the International Statistical Classification of Diseases and Related Health Problems classification (ICD-10), as cardiovascular cause (I00-I99), pulmonary cause (J00-J99), neoplastic cause (C00-D48), renal cause (N00-N99), caused by multiple organ dysfunction (R65-10) or of unknown origin (R99). Deaths were classified as unknown when no specific cause could be identified. Patients lost to follow-up were censored as alive on the day of the last visit.
Secondary endpoints included early and delayed procedure-related complications and predictive risk factors for death.
Statistical analyses
Data are summarized as frequencies and percentages for categorical variables. Quantitative variables are expressed as means ± standard deviations. Qualitative data were compared using Fisher's exact test, while quantitative data were compared using the Mann-Whitney test. Survival curves were estimated using Kaplan-Meier method, with log-rank tests for comparisons. The prognostic relevance of different characteristics to long-term survival was assessed in univariate and multivariable fashion using Cox's proportional hazards regression analysis. In addition to age and sex, all values with P ≤ 0.2 in the univariate analysis were used for the multivariable analysis. All tests were two-sided at the 0.05 significance level. All statistical analyses were carried out using SPSS for Windows, version 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Study population
From January 2004 to July 2014, 62 nonagenarian patients were referred for pacemaker replacement. Patient characteristics are described in Table 1 . The mean age was 93.3 ± 2.9 years at the time of replacement (range, 90-104 years) and 50% were men. Most patients were living at home (36 patients, 58.1%).
The mean age at first implantation was 81.9 ± 7.7 years (range, 53-95 years). Therefore, the mean delay between first implantation and study inclusion was 11.4 ± 6.8 years. For most patients (52 patients, 83.9%) this was the first device replacement, while eight patients had already had one replacement and two patients had undergone two replacements.
The main indications at first implantation were high degree AV block (63.0%) and sinus node dysfunction (22.6%). Accordingly, most patients had a dual-chamber pacemaker implanted during the first procedure (45 patients, 72.6%) and pacing was considered as ''physiological'' for 79.0%.
Device replacement was elective for most patients. However, two patients were hospitalized for acute heart failure secondary to AV block, the device having reached the elective replacement index.
Procedural characteristics and short-term outcome
Procedures were straightforward, lasting for an average of 35.7 ± 17.2 minutes, and were performed with local anaesthesia using mild sedation. The mean hospital stay was 2.2 ± 1.1 days (range, 1-8 days). Only two patients had outpatient surgeries.
Among the 44 patients with a previously implanted dual-chamber pacemaker, 12 (27.3%) were in persistent or permanent AF at the time of replacement and were downgraded to a single-chamber device. One patient initially implanted for paroxysmal AV block with a single-chamber pacemaker was upgraded to a CRT-P device for overt heart failure symptoms due to left ventricular dysfunction. All patients previously implanted with CRT-P devices were offered the same device at the time of replacement.
At the time of device replacement, many patients were on a regimen of anticoagulant (19.3%) or antiplatelet (51.6%) therapies; the mean number of drugs was 5.4 ± 3.2.
One patient had transient confusion after the procedure. The two patients not scheduled for surgery and who were hospitalized for heart failure after reaching the elective replacement indicator improved after medical treatment. No significant haematoma requiring surgical evacuation occurred, including in patients receiving anticoagulant or antiplatelet drugs. Aspiration pneumonia occurred in a 97-year-old woman during the procedure, complicated by acute respiratory distress syndrome, leading to the patient's death a few hours later.
Long-term follow-up
The median duration of follow-up was 22.1 months (interquartile range, 11.8-39.8 months). Seven patients (11.3%) were lost to follow-up and were censored as alive on the day of the last visit. During follow-up, no patient had a pacemaker-related infection or a device/lead dysfunction requiring a redo intervention. Thirty-seven patients (59.7%) died. The median survival time was 30.2 months (2.5 years, 95% confidence interval [CI] 26.2-41.8 months) and none of the patients lived for more than 7 years. The survival curve of the population is shown in Fig. 1 . Survival rates at 1, 2 and 5 years were 84.2% (95% CI 71.8-91.5%), 66.9% (95% CI 51.8-78.2%) and 22.7% (95% CI 10.6-37.7%), respectively. Fifteen patients (40.5%) died from a cardiovascular cause, mainly of heart failure ( Table 2) . Despite inquiries made with the general practitioner or medical service (in the case of patients living in nursing homes), the cause of death remained unknown in 13 patients (35.1%). Data are expressed as number (%).
Predictors of mortality
Predictors of all-cause mortality in univariate and multivariable analyses are shown in Table 3 . Although not significant, there was a trend (P = 0.06) towards increased mortality risk depending on initial pacing indication (hazard ratio Fig. 2 ).
Discussion
The main findings in this study were the following:
• pacemaker replacement is a safe procedure in nonagenarians, with rare perioperative complications; Figure 2 . Survival depending on pacing mode, after removing cardiac resynchronization therapy-pacemaker recipients (three patients).
• one third of patients in sinus rhythm at initial implantation are in AF at the time of device replacement, allowing downgrading of the pacing mode; • median survival after replacement is 30 months (2.5 years); • AF and the absence of physiological pacing are predictors of mortality, highlighting that fact that DDD recipients in sinus rhythm at the time of replacement should be offered the same type of device.
To date, no studies have reported specifically on procedural safety and long-term outcomes after pacemaker replacement in nonagenarians, a particularly frail population. The percentage of the population aged > 90 years is expected to increase in the next decades. According to the American Social Security Administration, one of every four people aged 65 years today will live past the age of 90 years, and one of 10 people will live past 95 years [9] . Accordingly, many patients currently implanted with a pacemaker will require device replacement when they are nonagenarians.
Procedural safety
Many complications can occur after pacemaker implantation, such as haematoma, device-related infection, lead dislodgment or device extrusion. These complications affect approximately up to 9.5% of device recipients [10] . Women, underweight patients, low-volume centres and operators, dual-chamber devices, upgrading or lead revision and emergency out-of-hours procedures have been associated with a higher risk of complications [10] . In patients aged > 80 years, Udo et al. reported significant complication rates, mostly lead-related, of 9.8% within 2 months and 6.9% during long-term follow-up; these rates were not different to those in patients aged < 80 years [5] . Similarly, very elderly patients did not seem to have more complications than younger patients in other studies [11, 12] . However, in the largest epidemiological study published so far on pacemaker implantations, in the nonagenarian subgroup, including more than 12,000 patients from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample administrative database, Mandawat et al. demonstrated mortality and complication rates of 1.87% and 6.31%, respectively, which were modestly but significantly higher than those in septuagenarians and octogenarians [8] . These frail patients also had a significantly longer hospital stay (4.27 days) than younger patients, at an estimated cost of > $41,000. Severe co-morbidities and older age were strong predictors of mortality.
Generator change, although apparently a simple procedure, also has a high risk of complications, as up to 6.5% of patients can have adverse outcomes [13, 14] . These complications, mainly related to skin erosion and pocket infections, are influenced by operator experience, procedure duration and device type. The risk of infection was shown to be more frequent in case of non-infectious complications requiring redo procedures. In the REPLACE registry, authors prospectively assessed procedural-related complications associated with elective pacemaker or implantable cardioverter-defibrillator device replacements over 6 months of follow-up. Major complications occurred more frequently in patients needing material revisions, supporting careful decision-making when generator replacement is needed [15] . In our study, only one major complication occurred (an aspiration pneumonia during surgery leading to the patient's death the same day). No haematoma, pocket infection or lead-related complications were noted during the follow-up period. Only one patient had transient confusion after the procedure. Outpatient procedures were performed in two patients in our series, and may be a good choice for elderly patients, especially those living in nursing homes. However, many of these patients are on anticoagulant or antiplatelet therapies, and close monitoring of local complications (swelling, haematoma) may be necessary to avoid later serious adverse events.
Pacing mode and outcome
As the mean age at first implantation was 81.9 ± 7.7 years and the patients were mostly in sinus rhythm, a large number of patients (n = 44) had had atrial-based devices implanted previously. The optimal pacing mode has been a matter of debate for some time. In 2005, the United Kingdom Pacing and Cardiovascular Events (UKPACE) study showed that in elderly patients with high degree AV block, the pacing mode (VVI or DDD) did not influence the rate of deaths from all causes and the incidence of cardiovascular events [16] . Healey et al. published a meta-analysis about pacing modes to analyse whether an atrial-based pacing mode was associated with better long-term outcomes in device recipients, which included UKPACE [16] and four large studies (CTOPP [17] , MOST [18] , PASE [19] and the Danish trial [20, 21] ). The authors showed that, compared with ventricular pacing, the use of atrial-based pacing does not improve survival or reduce rates of heart failure or cardiovascular death. However, physiological pacing was shown to reduce the incidence of AF (HR 0.8, 95% CI 0.72-0.89; P = 0.00003) and to slightly reduce the incidence of stroke (HR 0.81, 95% CI 0.67-0.99; P = 0.035) [22] . However, in the five trials in this meta-analysis, the average age of the patients included was approximately 72-80 years [17] [18] [19] [20] [21] 23] . In very elderly patients (≥ 80 years), mode of pacing was not found to be a predictor of all-cause mortality [24] , and no detrimental effect of VVI pacing on cognitive function was demonstrated [25] . In our study, among the 44 patients initially in sinus rhythm and implanted with dual-chamber devices, 12 patients (27.3%) were in permanent AF at the time of device replacement and were downgraded to singlechamber devices. The remaining patients were offered a replacement with a dual-chamber pacemaker, although one may argue that the cost difference between these devices (approximately D 500) and the uncertain clinical benefit may advocate the systematic replacement of dual-chamber pacemakers with single-chamber devices in nonagenarians in sinus rhythm. However, as demonstrated in our study, AF and non-physiological pacing were predictors of mortality, with HRs of 2.47 and 2.20, respectively. These data suggest that dual-chamber pacemakers in patients in sinus rhythm should be replaced with the same type of device and not be downgraded to a single-chamber device.
Long-term survival
During follow-up, none of the patients needed a redo procedure for device/lead failure or haematoma. No pocket or lead infections occurred. Among the study population, 37 patients (59.7%) died, mainly from unknown or cardiovascular causes, and survival rates were 84.2% at 1 year, 66.9% at 2 years and 22.7% at 5 years; the median survival time was 30.2 months. These mortality rates are similar to those described previously by Udo et al. in a population of octogenarians and nonagenarians implanted for the first time (86%, 75% and 49% after 1, 2 and 5 years [5] ), and in nonagenarian non-recipients of pacemakers [26] .
In a prospective community-based study, Formiga et al. found that better cognitive status and fewer co-morbidities (evaluated by the Charlson Co-morbidity Index) were the best predictors for identifying which nonagenarians will die after a 5-year follow-up period [26] , although this was not found in our study.
Study limitations
We acknowledge some limitations in our study. Our analysis was performed as a retrospective review of a cohort of patients, with the inherent limitations of such studies (i.e. some patients were lost to follow-up). Furthermore, the limited number of patients does not allow precise determination of predictive factors of mortality. Lastly, despite inquiries made with the general practitioner or medical service (in case of nursing homes), the cause of death remained unknown in 13 patients (35.1%), in whom the devices were not interrogated post mortem.
Conclusions
Pacemaker replacement in nonagenarians is a safe and straightforward procedure, with rare complications occurring during hospitalization. This procedure can be performed securely in this old and frail population, and is useful for a significant period of time, with patients living for a median of 2.5 years afterwards. One third of patients in sinus rhythm at initial implantation are in AF at the time of device replacement, allowing downgrading of the pacing mode. However, for patients in sinus rhythm at the time of replacement, a dual-chamber pacemaker should be proposed, as non-physiological pacing seems to be a predictor of mortality.
